Nimotuzumab is thus the only anti-EGF-R mAb that can be chronically used3, in contrast to cetuximab and panitumumab, for which skin toxicity often determines the need of dose reduction or therapy discontinuation. The gene discussed is EGFR; the disease is dermatological toxicity.